A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer
Latest Information Update: 30 Dec 2024
Price :
$35 *
At a glance
- Drugs Fruquintinib (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 30 Dec 2024 New trial record